The Cambridge startup that lets scientists print their own proteins just minted $15.5M funding — TFN

Nuclera, a Cambridge-based biotechnology company, raised $15.5 million in Series B funding, bringing their total to $58 million. They have secured a total of $83.3 million from various investors, including M&G, Amadeus Capital Partners, E Ink, RT Partners, Future Planet Capital, British Business Bank Future Fund, and G. K. Goh. This funding will accelerate the commercial launch of their eProtein desktop bioprinter, which streamlines protein development for scientists. Nuclera aims to revolutionize protein expression screening by offering a single optimized workflow for drug discovery and bio-innovation.

Nuclera Secures $15.5 Million to Accelerate Commercial Launch of eProtein Bioprinter

Nuclera is a Cambridge-based biotechnology company focused on accelerating protein expression workflows. Their eProtein desktop bioprinter aims to simplify and expedite the process of protein development for research, offering a solution for scientists facing time-consuming methods.

A Cambridge-based biotechnology company accelerating protein expression workflows with a desktop bioprinter.

3 years ago

Nuclera Secures $15.5 Million to Accelerate Commercial Launch of eProtein Bioprinter

Covered on